Collaborate Explore Discover

More documents

Recommendations

Info

Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transductionmodulator and metastasis suppressor. Cell Res 18(4):452-7, 2008.# Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, KocherginskyM, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving proteinkinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res 69(1):65-74, 2009.* Granovsky AE, Clark MC, McElheny D, Heil G, Hong J, Liu X, Kim Y,Joachimiak G, Joachimiak A, Koide S, Rosner MR. Raf kinase inhibitory proteinfunction is regulated via a flexible pocket and novel phosphorylation-dependentmechanism. Mol Cell Biol 29(5):1306-20, 2009.* Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM,Minn AJ, Rosner MR. Raf kinase inhibitory protein suppresses a metastasissignalling cascade involving LIN28 and let-7. EMBO J 28(4):347-58, 2009.Roux, Benoit PhDBanavali NK, Roux B. Flexibility and charge asymmetry in the activation loopof Src tyrosine kinases. Proteins 74(2):378-89, 2009.Gan W, Roux B. Binding specificity of SH2 domains: Insight from free energysimulations. Proteins 74(4):996-1007, 2009.Pan AC, Roux B. Building Markov state models along pathways to determinefree energies and rates of transitions. J Chem Phys 129(6):064107, 2008.Pan AC, Sezer D, Roux B. Finding transition pathways using the string methodwith swarms of trajectories. J Phys Chem B 112(11):3432-40, 2008.Yang S, Roux B. Src kinase conformational activation: thermodynamics,pathways, and mechanisms. PLoS Comput Biol 4(3):e1000047, 2008.Deng Y, Roux B. Computation of binding free energy with molecular dynamicsand grand canonical Monte Carlo simulations. J Chem Phys 128(11):115103,2008.Yang S, Banavali NK, Roux B. Mapping the conformational transition in Srcactivation by cumulating the information from multiple molecular dynamicstrajectories. Proc Natl Acad Sci U S A 106(10):3776-81, 2009.Deng Y, Roux B. Computations of standard binding free energies withmolecular dynamics simulations. J Phys Chem B 113(8):2234-46, 2009.Park S, Bardhan JP, Roux B, Makowski L. Simulated x-ray scattering of proteinsolutions using explicit-solvent models. J Chem Phys 130(13):134114, 2009.Freddolino PL, Park S, Roux B, Schulten K. Force field bias in protein foldingsimulations. Biophys J 96(9):3772-80, 2009.Salgia, Ravi MD, PhD# Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R,Stadler WM, Vokes EE, Fleming GF. Efficacy and safety of bevacizumab pluserlotinib for patients with recurrent ovarian, primary peritoneal, and fallopiantube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.Gynecol Oncol 110(1):49-55, 2008.# Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, MackinnonAC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, SchwartzS, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, SouliiL, Bindokas VP, Szeto LL, Gordon GJ, Bue. Paxillin is a target for somaticmutations in lung cancer: implications for cell growth and invasion. Cancer Res68(1):132-42, 2008.Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, SalgiaR. C. elegans as a model organism for in vivo screening in cancer: effects ofhuman c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer BiolTher 7(6):856-63, 2008.Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responsesto autoantigens are associated with tumor destruction and favorable clinicaloutcomes without autoimmunity. Clin Cancer Res 14(12):3896-905, 2008.# Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE.Randomized phase II Study of carboplatin and etoposide with or without thebcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lungcancer: CALGB 30103. J Clin Oncol 26(6):870-6, 2008.# Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El DinaliM, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S,Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosinekinase is a potential novel therapeutic target for head and neck squamous cellcarcinoma. Cancer Res 69(7):3021-31, 2009.Solway, Julian MDHe D, Natarajan V, Stern R, Gorshkova IA, Solway J, Spannhake EW, Zhao Y.Lysophosphatidic acid-induced transactivation of epidermal growth factorreceptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) releasevia C/EBPbeta in human bronchial epithelial cells. Biochem J 412(1):153-62,2008.Pinto LH, Eaton E, Chen B, Fleisher J, Shuster D, McCauley J, Kedainis D,Siepka SM, Shimomura K, Song EJ, Husain A, Lakser OJ, Mitchell RW, DowellML, Brown M, Camoretti-Mercado B, Naclerio R, Sperling AI, Levin SI, TurekFW, Solway J. Gene-environment interactions in a mutant mouse kindred withnative airway constrictor hyperresponsiveness. Mamm Genome 19(1):2-14,2008.Sosnick, Tobin PhDStrickland D, Moffat K, Sosnick TR. Light-activated DNA binding in a designedallosteric protein. Proc Natl Acad Sci U S A 105(31):10709-14, 2008.Tang, Wei-Jen PhD* Yfanti C, Mengele K, Gkazepis A, Weirich G, Giersig C, Kuo WL, TangWJ, Rosner M, Schmitt M. Expression of metalloprotease insulin-degradingenzyme insulysin in normal and malignant human tissues. Int J Mol Med22(4):421-31, 2008.* Weirich G, Mengele K, Yfanti C, Gkazepis A, Hellmann D, Welk A, Giersig C,Kuo WL, Rosner MR, Tang WJ, Schmitt M. Immunohistochemical evidence forubiquitous distribution of the metalloendoprotease insulin-degrading enzyme(IDE, insulysin) in human non-malignant tissues and tumor cell lines. BiolChem 389(11):1441-5, 2008.Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington NL, Tang WJ.Molecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme. Biochemistry47(48):12822-34, 2008.Guo Q, Jureller JE, Warren JT, Solomaha E, Florian J, Tang WJ. Protein-proteindocking and analysis reveal that two homologous bacterial adenylyl cyclasetoxins interact with calmodulin differently. J Biol Chem 283(35):23836-45,2008.Taha HM, Schmidt J, Gottle M, Suryanarayana S, Shen Y, Tang WJ, Gille A,Geduhn J, Konig B, Dove S, Seifert R. Molecular Analysis of the Interactionof Anthrax Adenylyl Cyclase Toxin, Edema Factor, with 2’(3’)-O-(N-(methyl)anthraniloyl)-Substituted Purine and Pyrimidine Nucleotides. Mol Pharmacol75(3):693-703, 2009.Spangler CM, Spangler C, Gottle M, Shen Y, Tang WJ, Seifert R, Schaferling M.A fluorimetric assay for real-time monitoring of adenylyl cyclase activity basedon terbium norfloxacin. Anal Biochem. 381(1):86-93, 2008.Kim C, Wilcox-Adelman S, Sano Y, Tang WJ, Collier RJ, Park JM.Antiinflammatory cAMP signaling and cell migration genes co-opted by theanthrax bacillus. Proc Natl Acad Sci U S A 105(16):6150-5, 2008.Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, DuesberyNS, Leppla SH, Tang WJ, Frankel AE. Anthrax toxin-induced shock in rats isassociated with pulmonary edema and hemorrhage. Microb Pathog 44(6):467-72, 2008.Turner, Jerrold MD, PhD# Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 andclaudin-2 expression is elevated in inflammatory bowel disease and maycontribute to early neoplastic transformation. Lab Invest 88(10):1110-20, 2008.Shen L, Weber CR, Turner JR. The tight junction protein complex undergoesrapid and continuous molecular remodeling at steady state. J Cell Biol181(4):683-95, 2008.Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK,Alrefai WA. Modulation of ileal bile acid transporter (ASBT) activity bydepletion of plasma membrane cholesterol: association with lipid rafts. Am JPhysiol Gastrointest Liver Physiol 294(2):G489-97, 2008.Gill RK, Pant N, Saksena S, Singla A, Nazir TM, Vohwinkel L, Turner JR,Goldstein J, Alrefai WA, Dudeja PK. Function, expression, and characterizationof the serotonin transporter in the native human intestine. Am J PhysiolGastrointest Liver Physiol 294(1):G254-62, 2008.24UCCRC SCIENTIFIC REPORT 2009
Yu D, Turner JR. Stimulus-induced reorganization of tight junction structure:the role of membrane traffic. Biochim Biophys Acta 1778(3):709-16, 2008.Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, AbrahamC, Turner JR. Targeted epithelial tight junction dysfunction causesimmune activation and contributes to development of experimental colitis.Gastroenterology 136(2):551-63, 2009.White, Kevin PhD# Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, LiuJ, Khramtsov A, Tretiakova MS, Krausz TN, Olopade OI, Rimm DL, White KP.Genomic analysis of estrogen cascade reveals histone variant H2A.Z associatedwith breast cancer progression. Mol Syst Biol. 4:188, 2008.Gauhar Z, Sun LV, Hua S, Mason CE, Fuchs F, Li TR, Boutros M, White KP.Genomic mapping of binding regions for the Ecdysone receptor proteincomplex. Genome Res 19(6):1006-13, 2009.Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Negre N,Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP. Analysis of Drosophilasegmentation network identifies a JNK pathway factor overexpressed in kidneycancer. Science 323(5918):1218-22, 2009.Cell Signaling &Gene RegulationUCCRC SCIENTIFIC REPORT 200925
Page 1 and 2: Collaborate Explore Discover2008-20
Page 3 and 4: Immunology& CancerClinical & Experi
Page 6 and 7: AdministrationUCCRC Executive Commi
Page 8 and 9: Program 1Cell Signaling and Gene Re
Page 10 and 11: 8MembersInvestigator*Kenneth Alexan
Page 12 and 13: Theme: Molecular Mechanisms of Apop
Page 14 and 15: Theme: Cell Motility, Cell-Cell Adh
Page 16 and 17: Theme: Systems Biology and Genetic
Page 18 and 19: Theme: Developmental BiologyIlaria
Page 20 and 21: Additional Program Highlights*Resea
Page 22 and 23: Selected Publications* : Intraprogr
Page 24 and 25: Lang D, Mascarenhas JB, Powell SK,
Page 28 and 29: Selected Major Grants and AwardsThe
Page 30 and 31: Program 2Molecular Genetics and Hem
Page 32 and 33: MembersInvestigator*John Anastasi M
Page 34 and 35: Theme: Pathogenesis of LeukemiaDoro
Page 36 and 37: The ultimate goals of the laborator
Page 42 and 43: * Knight JA, Skol AD, Shinde A, Has
Page 44 and 45: * # Gordon MK, Sher D, Karrison T,
Page 46 and 47: Program 3Immunology and CancerScann
Page 48 and 49: MembersInvestigator*Erin Adams PhDM
Page 50 and 51: and αβ TCRs are well known, the l
Page 52 and 53: transcriptional profile in the tumo
Page 54 and 55: ••The impact of regulatory T ce
Page 58 and 59: Storb, Ursula MD# Longerich S, Orel
Page 60 and 61: Dr. Susan Cohn with a patientProgra
Page 62 and 63: 60MembersInvestigator*Douglas Bisho
Page 64 and 65: compared to mice treated with IP ci
Page 66 and 67: Using a structure-based rationale,
Page 68 and 69: incorporation of other genetic elem
Page 74 and 75: Hart, John MD* # Dougherty U, Sehde
Page 76 and 77:
Nanda, Rita MD# Wei M, Xu J, Dignam
Page 78 and 79:
# Yang C, Karczmar GS, Medved M, Ot
Page 80 and 81:
Selected Major Grants and AwardsThe
Page 82 and 83:
Program 5Advanced Imaging
Page 84 and 85:
MembersInvestigator*Hiroyuki Abe MD
Page 86 and 87:
in as many as 86% of the measuremen
Page 88 and 89:
investigators and engineers from co
Page 90 and 91:
have important clinical implication
Page 92 and 93:
Theme: Image-Guided TherapyCharles
Page 94 and 95:
irradiated to a variety of doses ne
Page 96 and 97:
Selected Publications* : Intraprogr
Page 98 and 99:
* Jansen SA, Fan X, Karczmar GS, Ab
Page 100 and 101:
Program 6Cancer Risk and Prevention
Page 102 and 103:
MembersInvestigator*Habibul Ahsan M
Page 104 and 105:
to prostate cancer. The work has ma
Page 106 and 107:
Dr. Ahsan’s team showed that sele
Page 108 and 109:
Theme: Psychological and Bio-Behavi
Page 110 and 111:
Daniel McGehee, PhDAssociate Profes
Page 112 and 113:
Sarah Gehlert, PhDProfessor of the
Page 114 and 115:
Selected New Funding•• Lisa San
Page 116 and 117:
Selected Publications* : Intraprogr
Page 118 and 119:
Gehlert, Sarah PhD* Gehlert S, Sohm
Page 120 and 121:
Olopade, Olufunmilayo MBBS* Bradbur
Page 122 and 123:
Clinical Trials ActivityDr. Alessan
Page 124 and 125:
The clinical trials activity of the
Page 126 and 127:
Shared ResourcesDr. Vytas Bindokas
Page 128 and 129:
Biostatistics Core FacilityScientif
Page 130 and 131:
collaborations. The Facility mainta
Page 132 and 133:
The services provided include:•
Page 134 and 135:
Other Resources and Centers
Page 136 and 137:
Cancer Resource CenterThe UCCRC off
Page 138 and 139:
CECOS has successfully developed an
Page 140 and 141:
Committee on ImmunologyThe Committe
Page 142 and 143:
The University of Chicago Medical C
Page 144 and 145:
HighlightsThe Gwen and Jules Knapp
Page 146 and 147:
Leukemia and Lymphoma Society Speci
Page 148 and 149:
Institute for Genomics and Systems
Page 150 and 151:
Systems Biology Approach for the St
Page 152 and 153:
Immunology and Cancer ProgramMaria-
Page 154 and 155:
Cancer Risk and Prevention ProgramA
Page 156:
www.uccrc.uchicago.eduEditor: Hoyee
show all

Collaborate Explore Discover

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?